Merck's Tulisokibart Shows Promise in Hidradenitis Suppurativa Trial

Merck has announced positive results from its Phase 2 trial evaluating tulisokibart, an investigational monoclonal antibody, in patients with moderate to severe hidradenitis suppurativa. The trial met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 at week 16.

In the trial, 72% of patients receiving high-dose tulisokibart (480 mg every two weeks) and 64% receiving medium-dose (480 mg every four weeks) achieved HiSCR50, compared to 35% in the placebo group. The low-dose group (240 mg every four weeks) achieved a 52% response rate.

Tulisokibart targets tumor necrosis factor-like cytokine 1A and is being evaluated in six disease indications. Phase 3 studies are underway in ulcerative colitis and Crohn’s disease.